(NASDAQ:NVAX) have caught the attention of investors. Given that its average daily volume over the 30 days has been 8.63M shares a day, this signifies a pretty significant change over the norm. The company has a market cap of $53.28B.
News headlines about Novavax (NASDAQ:NVAX) have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern also assigned media headlines about the biopharmaceutical company an impact score of 47.342935642259 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future. The acquisition was disclosed in a document filed with the SEC, which is available through this link.
On the other hand Novavax Inc (NASDAQ:NVAX) has Relative Strength Index (RSI 14) of 74.93 along with Average True Range (ATR 14) of 0.07. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping analysts' consensus estimates of ($0.16) by $0.01, Bloomberg Earnings reports. The Return on Equity (ROE) value stands at 452.8%. The firm had revenue of $5.68 million for the quarter, compared to analyst estimates of $6.17 million.
In the market the company is trading up by 5.15% since yesterday's close of 1.36 and is one of the top gainers in today's market. The firm's revenue was up 158.5% on a year-over-year basis. During the same period in the prior year, the company earned ($0.24) earnings per share. sell-side analysts predict that Novavax, Inc. will post -0.62 EPS for the current fiscal year.
These funds have shifted positions in (NVAX). Looking at the stock's movement on the chart, Novavax, Inc. recorded a 52-week high of $1.78. Metropolitan Life Insurance Co/ny controls 176,105 shares valued at $201,000. The stock experienced a fall in short interest from September 29, 2017 to October 13, 2017 of -5.94%.
Investors are feeling more bullish on Novavax Inc lately if you watch the downtick in short interest. Wolverine Trading, LLC controls 35,800 shares worth $41,000. Cantor Fitzgerald reissued a "hold" rating and set a $2.00 price objective on shares of Novavax in a research report on Wednesday, November 8th. Zacks Investment Research downgraded Novavax from a "hold" rating to a "sell" rating in a research report on Thursday, November 16th.
Taking a broader look at the analyst consensus, according to 4 analysts Novavax Inc (NASDAQ:NVAX)'s price will reach at $1.67 during 52 weeks.
On October 6, 2017 Seaport Global Securities reiterated a "Neutral" rating on the stock. A negative earnings surprise will usually result in a decline in share price. Finally, BidaskClub raised Novavax from a "sell" rating to a "hold" rating in a report on Monday, August 14th. (NASDAQ) as Buy, 0 analysts given Outperform signal, 2 reported Hold, and 0 analysts rated the stock as Sell. The stock has a consensus rating of "Hold" and an average target price of $3.12.
About Novavax Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The company operates in the Healthcare sector with a market capitalization of 395460. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.
Institutions own 37.63% of Novavax, Inc. Analysts study insider data to get a sense of sense of what key shareholders think about the outlook for a particular stock.